Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shanghai Fosun Pharmaceutical is moving forward with the proposed privatization of Shanghai Henlius Biotech through a merger by absorption. The company has dispatched a composite document outlining the merger details, including the expected timetable and recommendations from the Independent Board Committee. Shareholders are advised to review the terms and consider their options between the Cash Alternative and Share Alternative.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Looking Good for 2025,’ Says Investor About Nio Stock
- ‘The Bull Run Isn’t Over,’ Says Top Investor About Palantir Stock
- ‘There’s Hope for the Hopeless,’ Says Investor About Intel Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
